Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing

Journal of Immunology

Volumn 190, Issue 11, 2013, Pages 5874-5881

  Liang, Hua ^a   Deng, Liufu ^a   Chmura, Steven ^a   Burnette, Byron ^a   Liadis, Nicole ^a   Darga, Thomas ^a   Beckett, Michael A ^a   Lingen, Mark W ^a   Witt, MaryEllyn ^a   Weichselbaum, Ralph R ^a   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; IMMUNOREACTIVITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RADIATION INDUCED TUMOR EQUILIBRIUM; RADIOSENSITIVITY; T CELL DEPLETION; T LYMPHOCYTE; TUMOR CELL; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; NEOPLASM METASTASIS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84878044481     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202612     Document Type: Article

References (33)

1. Demicheli, R., E. Biganzoli, P. Boracchi, M. Greco, and M. W. Retsky. 2008. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res. 10: R83.
2. Klein, C. A. 2011. Framework models of tumor dormancy from patient-derived observations. Curr. Opin. Genet. Dev. 21: 42-49.
3. Darby, S., P. McGale, C. Correa, C. Taylor, R. Arriagada, M. Clarke, D. Cutter, C. Davies, M. Ewertz, J. Godwin, et al Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 2011. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378: 1707-1716.
4. Pilepich, M. V., K. Winter, C. A. Lawton, R. E. Krisch, H. B. Wolkov, B. Movsas, E. B. Hug, S. O. Asbell, and D. Grignon. 2005. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61: 1285-1290. (Pubitemid 40470408)
5. Char, D. H., S. Kroll, T. L. Phillips, and J. M. Quivey. 2002. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 109: 1850-1854.
6. Chao, K. S., G. Ozyigit, B. N. Tran, M. Cengiz, J. F. Dempsey, and D. A. Low. 2003. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 55: 312-321. (Pubitemid 36069088)
7. Aguirre-Ghiso, J. A. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7: 834-846. (Pubitemid 350006258)
8. Goss, P. E., and A. F. Chambers. 2010. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10: 871-877.
9. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907. (Pubitemid 350231320)
10. Salama, J. K., S. J. Chmura, N. Mehta, K. M. Yenice, W. M. Stadler, E. E. Vokes, D. J. Haraf, S. Hellman, and R. R. Weichselbaum. 2008. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin. Cancer Res. 14: 5255-5259.
11. Salama, J. K., M. D. Hasselle, S. J. Chmura, R. Malik, N. Mehta, K. M. Yenice, V. M. Villaflor, W. M. Stadler, P. C. Hoffman, E. E. Cohen, et al. 2012. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118: 2962-2970.
12. Lee, Y., S. L. Auh, Y. Wang, B. Burnette, Y. Wang, Y. Meng, M. Beckett, R. Sharma, R. Chin, T. Tu, et al. 2009. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114: 589-595.
13. Park, S., Z. Jiang, E. D. Mortenson, L. Deng, O. Radkevich-Brown, X. Yang, H. Sattar, Y. Wang, N. K. Brown, M. Greene, et al. 2010. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18: 160-170.
14. Burnette, B. C., H. Liang, Y. Lee, L. Chlewicki, N. N. Khodarev, R. R. Weichselbaum, Y.-X. Fu, and S. L. Auh. 2011. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71: 2488-2496.
15. Lugade, A. A., E. W. Sorensen, S. A. Gerber, J. P. Moran, J. G. Frelinger, and E. M. Lord. 2008. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J. Immunol. 180: 3132-3139.
16. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
17. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567. (Pubitemid 36597102)
18. Zou, W., and L. Chen. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8: 467-477. (Pubitemid 351733418)
19. Wolstenholme, J. T., J. A. Warner, M. I. Capparuccini, K. J. Archer, K. L. Shelton, and M. F. Miles. 2011. Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice. PLoS ONE 6: e21100.
20. Koolhaas, J. M., S. F. de Boer, C. M. Coppens, and B. Buwalda. 2010. Neuroendocrinology of coping styles: towards understanding the biology of individual variation. Front. Neuroendocrinol. 31: 307-321.
21. Martin, M. E., J. A. Dieter, Z. Luo, N. Baumgarth, and J. V. Solnick. 2012. Predicting the outcome of infectious diseases: variability among inbred mice as a new and powerful tool for biomarker discovery. MBio 3: e00199-12.
22. Postow, M. A., M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan, S. Kitano, Z. Mu, T. Rasalan, M. Adamow, E. Ritter, et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366: 925-931.
23. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6: 836-848. (Pubitemid 44631652)
24. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
25. Matsushita, H., M. D. Vesely, D. C. Koboldt, C. G. Rickert, R. Uppaluri, V. J. Magrini, C. D. Arthur, J. M. White, Y. S. Chen, L. K. Shea, et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404.
26. DuPage, M., C. Mazumdar, L. M. Schmidt, A. F. Cheung, and T. Jacks. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409.
27. Müller-Hermelink, N., H. Braumüller, B. Pichler, T. Wieder, R. Mailhammer, K. Schaak, K. Ghoreschi, A. Yazdi, R. Haubner, C. A. Sander, et al. 2008. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13: 507-518. (Pubitemid 351763899)
28. Zhou, Q., M. E. Munger, R. G. Veenstra, B. J. Weigel, M. Hirashima, D. H. Munn, W. J. Murphy, M. Azuma, A. C. Anderson, V. K. Kuchroo, and B. R. Blazar. 2011. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117: 4501-4510.
29. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207: 2187-2194.
30. Fourcade, J., Z. Sun, M. Benallaoua, P. Guillaume, I. F. Luescher, C. Sander, J. M. Kirkwood, V. Kuchroo, and H. M. Zarour. 2010. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207: 2175-2186.
31. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
32. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
33. Croft, M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9: 271-285.